Stephanie Davis
Stock Analyst at Barclays
(1.24)
# 3,402
Out of 4,832 analysts
95
Total ratings
33.85%
Success rate
-12.1%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $174.49 | +6.02% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $39.11 | +15.06% | 3 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $11.01 | -54.59% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $60.43 | +24.11% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.87 | +19.25% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.30 | +39.53% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $9.27 | +104.96% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $279.00 | +3.94% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $22.87 | +4.96% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $148.26 | -10.29% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $28.00 | +107.14% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.07 | -2.28% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $0.31 | +142.72% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $250.01 | -0.40% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $26.10 | +11.11% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.62 | +346.19% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.68 | +56.83% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $241.20 | -3.40% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $4.29 | +296.27% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $96.99 | -21.64% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $174.49
Upside: +6.02%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $39.11
Upside: +15.06%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $11.01
Upside: -54.59%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $60.43
Upside: +24.11%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.87
Upside: +19.25%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.30
Upside: +39.53%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $9.27
Upside: +104.96%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $279.00
Upside: +3.94%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.87
Upside: +4.96%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $148.26
Upside: -10.29%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $28.00
Upside: +107.14%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.07
Upside: -2.28%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $0.31
Upside: +142.72%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $250.01
Upside: -0.40%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $26.10
Upside: +11.11%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.62
Upside: +346.19%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.68
Upside: +56.83%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $241.20
Upside: -3.40%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $4.29
Upside: +296.27%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $96.99
Upside: -21.64%